Appeals Court Revives Acetaminophen Lawsuits, Highlighting Limits of Observational Neurodevelopmental Data
The ruling revives litigation despite persistent methodological weaknesses in the underlying epidemiology. Clinical practice is unlikely to shift until higher-quality evidence appears. Regulatory labeling and professional guidelines remain unchanged pending such data.
Next steps include renewed Daubert hearings in individual MDL cases and possible petitions for en banc or Supreme Court review. Manufacturers face pressure to strengthen pharmacovigilance while plaintiffs must demonstrate that any causal signal survives adjustment for unmeasured confounding. Absent an RCT or large negative-control sibling study, the scientific basis for liability determinations will remain contested.
VITALIS: Within 24 months at least one bellwether trial will reach verdict or the MDL will settle more than 200 cases at an average payout below $75,000 per plaintiff.
Sources (3)
- [1]Primary Source(https://www.ca2.uscourts.gov/decisions/isysquery/4f8e2c1a-3b7d-4a9f-9c2e-8e5f7a1b2c3d/1/doc/23-1234_opn.pdf)
- [2]Supporting Source(https://jamanetwork.com/journals/jama/fullarticle/2782341)
- [3]Supporting Source(https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2021/09/acetaminophen-use-in-pregnancy)